Program
ART5803
A development code. Also written as “ART5803-Cohort D”.
Its studies are mostly in Autoimmune Diseases of the Nervous System · Encephalitis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arialys Therapeutics | 20 open or running | phase 1since Aug 15, 2024 | Aug 15, 2024 | none ahead |
| Arialys Australia Pty | 11 open or running | phase 2since Jun 19, 2025 | Jun 19, 2025 | Nov 30, 2027phase 2 · NCT07093333 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2024First study: phase 1 study in Autoimmune Diseases of the Nervous SystemNew to Arialys TherapeuticsArialys Therapeutics · NCT06575153 · 64 enrolled · Australia
- Dec 23, 2024Phase 1 study in Autoimmune Diseases of the Nervous SystemArialys Therapeutics · NCT06753955 · 7 enrolled · Australia
- Jun 19, 2025Arialys Australia Pty's first study: phase 2 study in EncephalitisNew to Arialys Australia PtyArialys Australia Pty · NCT07093333 · 30 planned · South Korea
Ahead
- Nov 30, 2027Primary completion: phase 2 study in EncephalitisArialys Australia Pty · NCT07093333
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07093333Encephalitis · South Korea | 2 | Recruiting | Arialys Australia Pty | Nov 30, 2027 | 30 |
| NCT06753955Autoimmune Diseases of the Nervous System · Australia | 1 | Completed | Arialys Therapeutics | Jul 2, 2025 | 7 |
| NCT06575153Autoimmune Diseases of the Nervous System · Australia | 1 | Completed | Arialys Therapeutics | Sep 11, 2025 | 64 |
How it is read
Names in the registry
- “ART5803”, 3 entries
- “ART5803-Cohort D”, 1 entry
Codes read as this program: ART5803.
Conditions, from the studies’ own filings
- Autoimmune Diseases of the Nervous System, 2 studies
- Encephalitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.